Tag: Histamine release

The incidence of atracurium-induced bronchospasm is reported to be between 0.2% and 1.5%. This adverse reaction, particularly concerning for patients with underlying respiratory conditions, hinges on a specific pharmacological mechanism that explains **how does atracurium cause bronchospasm**.

While cisatracurium is widely regarded for its cardiovascular stability, a 2017 retrospective cohort analysis of ICU patients found that hypotension occurred in nearly 59% of patients receiving continuous cisatracurium infusion. Although this number reflects underlying patient factors more than the drug's inherent risk, the inquiry, “Can cisatracurium cause hypotension?” warrants a deeper look into its pharmacological profile and potential mechanisms.

Over the past few years, the medical community has shifted away from the outdated and potentially insensitive term 'red man syndrome'. The syndrome is now more accurately and respectfully referred to as vancomycin infusion reaction (VIR) or vancomycin flushing syndrome (VFS). This change reflects a better understanding of the condition and a move toward more inclusive medical language.

The incidence of vancomycin infusion reaction (VIR), also known as red man syndrome, is estimated to be between 3.7% and 47% in patients receiving IV vancomycin. Understanding **how to avoid red man syndrome in vancomycin** is critical for patient safety.